Back to Directory
Synthistat
East of England
Founded 2025
Lentiviral vector yield enhancement via HDAC inhibitors and producer lines
Synthistat is a biotechnology company developing technologies to increase lentiviral vector production for cell and gene therapy manufacturing.
Its work combines designed histone deacetylase (HDAC) inhibitors with approaches to modify HEK293 producer cells. The company has reported early laboratory results from suppressing selected cellular restriction factors, while further producer-line engineering remains in development.
Synthistat also investigates potential oncology applications for its HDAC inhibitor candidates and plans to license manufacturing technologies.
Company Notes
Member of